Literature DB >> 19540555

Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system.

Emanuela D'Angelo1, Luigi G Spagnoli, Jaime Prat.   

Abstract

Uterine sarcomas are rare tumors that account for 3% to 7% of uterine cancers. Their histopathologic classification was revised by the World Health Organization (WHO) in 2003. The objectives of this study were to determine the frequency of different subtypes of uterine sarcoma applying the WHO criteria to a series of cases, compare the outcome of patients with different subtypes, and compare their immunoprofiles using a panel of immunomarkers. Thirty-four uterine sarcomas were identified for a 20-year period (1988-2008). Eighteen benign tumors of smooth muscle or endometrial stromal origin served as a comparison group. A tissue microarray was prepared and immunostaining performed for 10 selected oncoproteins involved in cell proliferation (Ki-67, P53, p16, and phosphatase and tensin homolog [PTEN]), cell differentiation (CD10, h-caldesmon, estrogen receptor, and progesterone receptor), and apoptosis (bcl-2 and Twist). Hierarchical clustering analysis of the immunohistochemical results was performed. The uterine sarcomas were classified as follows: 20 leiomyosarcomas, 9 endometrial stromal sarcomas, and 5 undifferentiated endometrial sarcomas. The outcome for patients with uterine sarcoma was poor, irrespective of histologic type, even for those with stage I tumors. Of the patients with follow-up available, 12 (67%) of 18 with leiomyosarcoma, 4 of 5 with undifferentiated sarcoma, and 4 of 7 with endometrial stromal sarcoma experienced recurrence and 8 patients with high-grade sarcomas died of tumor. In our series, most uterine sarcomas were leiomyosarcomas. Comparison was made between leiomyosarcomas that recurred and those with a favorable outcome and 3 patients with leiomyosarcoma without evidence of recurrence on long-term follow-up had tumors that were negative/low expressors of Ki-67, p53, p16, and Twist, with strong expression of bcl-2. A subset of undifferentiated endometrial sarcomas composed of cells with uniform nuclei may be a separate entity from those with nuclear anaplasia and may be related to low-grade endometrial stromal sarcomas. It may be possible to identify a subset of leiomyosarcomas with a favorable prognosis based on staining with a panel of immunomarkers for cell proliferation and apoptosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19540555     DOI: 10.1016/j.humpath.2009.03.018

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  17 in total

1.  An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas.

Authors:  Mary-Margaret L Allen; Jonathan J Douds; Sharon X Liang; Mohamed M Desouki; Vinita Parkash; Oluwole Fadare
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Significance of lymph node metastasis on survival of women with uterine adenosarcoma.

Authors:  Hiroko Machida; Michael J Nathenson; Tsuyoshi Takiuchi; Crystal L Adams; Jocelyn Garcia-Sayre; Koji Matsuo
Journal:  Gynecol Oncol       Date:  2017-01-18       Impact factor: 5.482

3.  Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers.

Authors:  Riitta Koivisto-Korander; Ralf Butzow; Anna-Maija Koivisto; Arto Leminen
Journal:  Tumour Biol       Date:  2010-12-16

4.  Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence.

Authors:  Amy Carroll; Pedro T Ramirez; Shannon N Westin; Pamela T Soliman; Mark F Munsell; Alpa M Nick; Kathleen M Schmeler; Ann H Klopp; Nicole D Fleming
Journal:  Gynecol Oncol       Date:  2014-10-28       Impact factor: 5.482

5.  A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study.

Authors:  Linda R Duska; John A Blessing; Jacob Rotmensch; Robert S Mannel; Parviz Hanjani; Peter G Rose; Don S Dizon
Journal:  Gynecol Oncol       Date:  2014-08-01       Impact factor: 5.482

6.  Expression of TWIST1, Snail, Slug, and NF-κB and methylation of the TWIST1 promoter in mammary phyllodes tumor.

Authors:  Sung-Im Do; Ji Yeon Kim; So Young Kang; Jae Joon Lee; Jeong Eon Lee; Seok Jin Nam; Eun Yoon Cho
Journal:  Tumour Biol       Date:  2012-11-14

7.  High expression of Twist is associated with tumor aggressiveness and poor prognosis in patients with renal cell carcinoma.

Authors:  Kojiro Ohba; Yasuyoshi Miyata; Tomohiro Matsuo; Akihiro Asai; Kensuke Mitsunari; Yohei Shida; Shigeru Kanda; Hideki Sakai
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

8.  The expression and characterization of endoglin in uterine leiomyosarcoma.

Authors:  Hiroko Mitsui; Kiyosumi Shibata; Yukio Mano; Shiro Suzuki; Tomokazu Umezu; Mika Mizuno; Eiko Yamamoto; Hiroaki Kajiyama; Tomomi Kotani; Takeshi Senga; Fumitaka Kikkawa
Journal:  Clin Exp Metastasis       Date:  2013-02-09       Impact factor: 5.150

9.  Molecular subtypes of uterine leiomyosarcoma and correlation with clinical outcome.

Authors:  Joyce N Barlin; Qin C Zhou; Mario M Leitao; Maria Bisogna; Narciso Olvera; Karin K Shih; Anders Jacobsen; Nikolaus Schultz; William D Tap; Martee L Hensley; Gary K Schwartz; Jeff Boyd; Li-Xuan Qin; Douglas A Levine
Journal:  Neoplasia       Date:  2015-02       Impact factor: 5.715

10.  Endometrial stromal tumors: immunohistochemical and molecular analysis of potential targets of tyrosine kinase inhibitors.

Authors:  Carmen Balañá; Enrique de Álava; Ruth Sardinha; Teresa Hernández; Susana Fraile; Francesc Tresserra; August Vidal; Maria Carmén Gómez; Aurora Astudillo; Nieves Hernández; Javier Saenz de Santamaría; Jaume Ordi; Luis Gonçalves; Rafael Ramos
Journal:  Clin Sarcoma Res       Date:  2013-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.